Current status and future directions in induction chemotherapy for head and neck cancer

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 1, 2013, Pages 57-74

  Argiris, Athanassios ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cetuximab; Chemoradiotherapy; Head and neck cancer; Induction therapy; Sequential therapy; TPF

Indexed keywords

ANTIBIOTIC AGENT; BETA TUBULIN; BETA TUBULIN II; BEVACIZUMAB; CABAZITAXEL; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; LAPATINIB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ALOPECIA; ANOREXIA; BLOOD TOXICITY; BLOODSTREAM INFECTION; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DERMATITIS; DIARRHEA; DISTANT FAILURE FREE SURVIVAL; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INDUCTION CHEMOTHERAPY; INFECTION; LEUKOPENIA; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ODYNOPHAGIA; ORGAN PRESERVATION; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION;

CETUXIMAB; CHEMORADIOTHERAPY; HEAD AND NECK CANCER; INDUCTION THERAPY; SEQUENTIAL THERAPY; TPF;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84884128171     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.03.001     Document Type: Review

References (83)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review 1975-2008, http://seer.cancer.gov/csr/1975_2008/.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62:10-29.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
4. Cmelak A.J. Current issues in combined modality therapy in locally advanced head and neck cancer. Critical Reviews in Oncology/Hematology 2012, 84:261-273.
5. Harari P.M. Promising new advances in head and neck radiotherapy. Annals of Oncology 2005, 16:vi13-vi19.
6. Bourhis J., Sire C., Graff P., et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncology 2012, 13:145-153.
7. Pignon J.P., Bourhis J., Domenge C., Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000, 355:949-955.
8. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical Cancer Research 1995, 1:1311-1318.
9. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine 2006, 354:567-578.
10. Harari P.M. Why has induction chemotherapy for advanced head and neck cancer become a united states community standard of practice?. Journal of Clinical Oncology 1997, 15:2050-2055.
11. Rooney M., Kish J., Jacobs J., et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985, 55:1123-1128.
12. Pignon J.P., le Maitre A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology 2009, 92:4-14. MACH-NC Collaborative Group.
13. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New England Journal of Medicine 1991, 324:1685-1690. The Department of Veterans Affairs Laryngeal Cancer Study Group.
14. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. Journal of the National Cancer Institute 1996, 88:890-899.
15. Domenge C., Hill C., Lefebvre J.L., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). British Journal of Cancer 2000, 83:1594-1598.
16. Urba S.G., Forastiere A.A., Wolf G.T., Esclamado R.M., McLaughlin P.W., Thornton A.F. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. Journal of Clinical Oncology 1994, 12:946-953.
17. Depondt J., Gehanno P., Martin M., et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993, 50:23-27.
18. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. Journal of the National Cancer Institute 1994, 86:265-272.
19. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. New England Journal of Medicine 2007, 357:1695-1704.
20. Vermorken J.B., Remenar E., Van Herpen C., et al. Long-term results from EORTC24971/TAX323: comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology 2011, 29. abstract 5530.
21. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. New England Journal of Medicine 2007, 357:1705-1715.
22. Lorch J.H., Goloubeva O., Haddad R.I., et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncology 2011, 12:153-159.
23. Pointreau Y., Garaud P., Chapet S., et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. Journal of the National Cancer Institute 2009, 101:498-506.
24. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. Journal of Clinical Oncology 2005, 23:8636-8645.
25. Blanchard P., Bourredjem A., Bourhis J., et al. Taxane-cisplatin-5FU as induction chemotherapy in locally advanced head and neck squamous cell carcinoma: an individual patient data meta-analysis of the MACH-NC group. Radiotherapy and Oncology 2011, 98. abstract 4.
26. Hitt R., Grau J.J., Lopez-Pousa A., et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). Journal of Clinical Oncology 2009, 27. abstract 6009.
27. Paccagnella A., Ghi M.G., Loreggian L., et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Annals of Oncology 2010, 21:1515-1522.
28. Cohen E.E., Karrison T., Kocherginsky M., et al. DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology 2012, 30. abstract 5500.
29. Haddad R.I., Rabinowits G., Tishler R.B., et al. The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). Journal of Clinical Oncology 2012, 30. abstract 5501.
30. Bristol-Myers Squib Company. Erbitux (cetuximab) prescribing information, 2012.
31. Burtness B., Goldwasser M.A., Flood W., Mattar B., Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 2005, 23:8646-8654. Eastern Cooperative Oncology Group.
32. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New England Journal of Medicine 2008, 359:1116-1127.
33. Mesia R., Vazquez S., Grau J.J., et al. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. Journal of Clinical Oncology 2009, 27. abstract 6015.
34. Remenar E., Lövey J., Koltai P., Horvath K., Gödeny M., Kasler M. First results of an uncontrolled, phase II trial of induction chemotherapy with cetuximab and docetaxel-cisplatin-5FU followed by cetuximab+radiotherapy in the responders in locally advanced resectable squamous cell cancer of the head and neck. European Journal of Cancer 2011, 47:S553.
35. Vermorken J.B., Remenar E., van den Weyngaert D., et al. Feasibility of cetuximab plus sequential platinum-based therapy (TPF→CRT) in advanced squamous cell head and neck cancer (SCCHN): a randomized phase II study of the EORTC Head and Neck Cancer Group (EORTC-HNCG # 24061). European Archives of Oto-Rhino-Laryngology 2012, 269:OP43.
36. Adkins D., Ley J., Nussenbaum B., et al. Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF+C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology 2011, 29. abstract 5560.
37. Kuperman D.I., Ley J., Nussenbaum B., et al. Safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in 30 patients (pts) with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology 2011, 29. abstract e16025.
38. Argiris A., Heron D.E., Smith R.P., et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. Journal of Clinical Oncology 2010, 28:5294-5300.
39. Kies M.S., Holsinger F.C., Lee J.J., et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. Journal of Clinical Oncology 2010, 28:8-14.
40. Seiwert T.Y., Haraf D.J., Cohen E.E., et al. A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). Journal of Clinical Oncology 2011, 29. abstract 5519.
41. D'Angelillo R.M., Trodella L., Cellini F., et al. Induction chemotherapy with cisplatin, 5-fluorouracil, and cetuximab followed by radiotherapy and cetuximab in head and neck cancers: preliminary results of a modern integrated approach. Journal of Clinical Oncology 2011, 29. abstract e16030.
42. Wanebo H.J., Ghebremichael M., Burtness B., et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). Journal of Clinical Oncology 2007, 25. abstract 6015.
43. Wanebo H.J., Ghebremichael M.S., Burtness B., et al. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG, E2303). Journal of Clinical Oncology 2010, 28. abstract 5513.
44. Zhao X., Guo Y., Zhu Y., et al. A prospective phase II study of induction chemotherapy and nimotuzumab for resectable locally advanced head and neck squamous cell carcinoma. Journal of Clinical Oncology 2012, 30. abstract e16039.
45. Lefebvre J., Pointreau Y., Rolland F., et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study. Journal of Clinical Oncology 2009, 27. abstract 6010.
46. Lefebvre J., Pointreau Y., Rolland F., et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study. Journal of Clinical Oncology 2011, 29. abstract 5501.
47. Kuhar C.G., Zakotnik B., Zumer B., Karner K., Jancar B., Strojan P. Induction TPF chemotherapy followed by concomitant RT, cetuximab and cisplatin for inoperable HN-SCC (phase II study EMR-62202-717). European Journal of Cancer 2011, 47. abstract 8545.
48. Strojan P., Zumer B., Karner K., et al. Concomitant cisplatin (CP)/cetuximab (CMb) chemoradioctherapy (ChT-RT) with induction TPF ChT in stage IV inoperable squamous cell carcinoma of the head and neck (SCC-HN): preliminary results of phase II study. European Archives of Oto-Rhino-Laryngology 2012, 269:PP59.
49. Rampino M., Bacigalupo A., Russi E., et al. Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. Anticancer Research 2012, 32:195-199.
50. Hainsworth J.D., Spigel D.R., Greco F.A., et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon Oncology Research Consortium. Cancer Journal 2011, 17:267-272.
51. Numico G., Franco P., Cristofano A., et al. Is the combination of cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Critical Reviews in Oncology/Hematology 2012, June (26). [Epub ahead of print].
52. Hainsworth J.D., Spigel D.R., Burris H.A., et al. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009, 115:2138-2146.
53. Lalami Y., Specenier P.M., Awada A., et al. EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiotherapy and Oncology 2012, 105:238-240.
54. Villaflor V.M., Haraf D., Salama J.K., et al. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Annals of Oncology 2011, 22:2501-2507.
55. Gilbert J., Murphy B., Dietrich M.S., et al. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer 2012, 118:1007-1013.
56. El Deen D.A., Toson E.A., El Morsy S.M. Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer. Medical Oncology 2012, 28:3367-3373.
57. Papadimitrakopoulou V. Paclitaxel, carboplatin and cetuximab (PCC) versus cetuximab, docetaxel, cisplatin and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma (HNSCC). http://clinicaltrials.gov/ct2/show/NCT01154920.
58. Marur S., Lee J.W., Cmelak A., et al. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Journal of Clinical Oncology 2012, 30. abstract 5566.
59. Jensen A.D., Krauss J., Potthoff K., et al. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. BMC Cancer 2011, 11. 182, 2407-11-182.
60. Merlano M. Induction chemotherapy followed by cetuximab plus definitive radiotherapy versus radiation plus cisplatin (INTERCEPTOR). http://clinicaltrials.gov/ct2/show/NCT00999700.
61. Merlano M.C., Denaro N., Curcio P., Colantonio I. Interceptor Group Induction chemotherapy followed by cetuximab plus definitive radiotherapy versus radiation plus cisplatin (INTERCEPTOR). European Archives of Oto-Rhino-Laryngology 2012, 269:PP122.
62. Cruz JJ, Hitt R. TPF plus cisplatin and radiotherapy vs TPF plus cetuximab and radiotherapy to treat head and neck cancer. http://clinicaltrials.gov/ct2/show/NCT00716391.
63. Paccagnella A., Ghi M.G., Floriani I., Gava A., Buffoli A Concomitant chemoradiation or RT/cetuximab versus induction TPF followed by chemoradiation or RT/cetuximab in locally advanced head and neck squamous cell carcinoma: a randomized phase III factorial study. Journal of Clinical Oncology 2011, 29. on behalf of the GSTTC Italian Collaborative Group, abstract TPS196.
64. Ghi M.G., Paccagnella A., Ferrari D., et al. Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): preliminary results on toxicity of a randomized, 2×2 factorial, phase II-III study (NCT01086826). Journal of Clinical Oncology 2012, 30. abstract 5513.
65. Haddad R. Docetaxel/cisplatin/5-fluorouracil (TPF) human papillomavirus (HPV) squamous cell carcinoma study. http://clinicaltrials.gov/ct2/show/NCT01221753.
66. Fury M. RAD001 (everolimus)+docetaxel+cisplatin as induction chemotherapy in patients with local-regional advanced head and neck cancer. http://clinicaltrials.gov/ct2/show/NCT00935961.
67. Faivre S. Everolimus, carboplatin, and paclitaxel in treating patients with locally advanced head and neck cancer that cannot be removed by surgery. http://clinicaltrials.gov/ct2/show/NCT01333085.
68. Cohen EE. Randomized study in locally advanced squamous cell carcinoma of head and neck. http://clinicaltrials.gov/ct2/show/NCT01133678.
69. Weiss J. Induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck. http://clinicaltrials.gov/ct2/show/NCT01412229.
70. Misiukiewicz K. Cabazitaxel - PF induction chemotherapy. http://clinicaltrials.gov/ct2/show/NCT01379339.
71. Mehrotra B., Schwartz D.L., Frank D., et al. Phase II trial of neoadjuvant chemotherapy for HPV-associated squamous cell carcinoma of the oropharynx followed by reduced-dose radiotherapy/chemoradiotherapy for responders or standard dose chemoradiotherapy for nonresponders. Journal of Clinical Oncology 2012, 30. abstract TPS5601.
72. Sturgis E.M., Ang K.K. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?. Journal of the National Comprehensive Cancer Network 2011, 9:665-673.
73. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology 2011, 29:4294-4301.
74. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiology, Biomarkers and Prevention 2005, 14:467-475.
75. Wang X.I., Thomas J., Zhang S. Changing trends in human papillomavirus-associated head and neck squamous cell carcinoma. Annals of Diagnostic Pathology 2012, 16:7-12.
76. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute 2008, 100:261-269.
77. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine 2010, 363:24-35.
78. Posner M.R., Lorch J.H., Goloubeva O., et al. Oropharynx cancer (OPC) in TAX 324: human papillomavirus (HPV) and survival. Journal of Clinical Oncology 2010, 28. abstract 5525.
79. Cullen K.J., Schumaker L., Nikitakis N., et al. Beta-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. Journal of Clinical Oncology 2009, 27:6222-6228.
80. Wu Y., Posner M.R., Schumaker L.M., et al. Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer 2012, 118:1811-1817.
81. Koh Y., Kim T.M., Jeon Y.K., et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Annals of Oncology 2009, 20:1414-1419.
82. Budach V. TPF sequential therapy: when and for whom?. Oncologist 2010, 15:13-18.
83. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. New England Journal of Medicine 2003, 349:2091-2098.